Lafutidine can improve the quality of gastric ulcer healing in humans: A randomized, controlled, multicenter trial

Inflammopharmacology

Volumn 14, Issue 5-6, 2006, Pages 226-230

  Higuchi, K ^a   Watanabe, T ^a   Tominaga, K ^a   Shiba, M ^a   Nakagawa, K ^b   Uno, H ^c   Kitada, K ^d   Satoh, H ^e   Chono, S ^f   Oshitani, N ^a   Fujiwara, Y ^a   Arakawa, T ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Higashisumiyoshi Morimoto Hospital   (Japan)

^c Oono Memorial Hospital   (Japan)

^d Aioi Hospital   (Japan)

^e Fujiidera City Hospital   (Japan)

^f Machida Gastrointestinal Hospital   (Japan)

Author keywords

Famotidine; Gastric ulcer; Lafutidine; Quality of ulcer healing

Indexed keywords

FAMOTIDINE; LAFUTIDINE;

ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAR; STOMACH ULCER; WOUND HEALING;

ACETAMIDES; ADULT; AGED; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; FAMOTIDINE; FEMALE; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES; STOMACH ULCER; TREATMENT OUTCOME; WOUND HEALING;

EID: 33845908483     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-0299-0     Document Type: Conference Paper

References (33)

1. Ajioka, H., Matsuura, N. and Miyake, H. (2002). High quality of ulcer healing in rats by lafutidine, a new-type histamine H2-receptor antagonist: Involvement of capsaicin-sensitive sensory neurons, Inflammopharmacology 10(4-6), 483-92.
2. Ajioka, H. and Miyake, H. (2000). Effect of FRG-8813, a new-type histamine H2-receptor antagonist, on the recurrence of gastric ulcer after healing by drug treatment in rats, Pharmacology 61, 83-90.
3. Arakawa, T., Higuchi, K., Fukuda, T. et al. (1998a). Prostaglandins in the stomach: an update, J. Clin.Gastroenterol. 27(Suppl 1), S1-11.
4. Arakawa, T. and Kobayashi, K. (1993a). Quality of ulcer healing: a new concept to rank healed peptic ulcers, Gastroenterolgia Japonica 28(Suppl 5), 158-62.
5. Arakawa, T., Nebiki, H., Uchida, T. et al. (1993b). Clinical assessment of quality of ulcer healing: A new endoscopic approach, Eur. J. Gastroenterol. Hepatol. 5 (Suppl. 3), S87-92.
6. Arakawa, T., Watanabe, T., Fukuda, T. et al. (1998b). Ulcer recurrence: cytokines and inflammatory response-dependent process, Dig. Dis. Sci. 43(9), 615-64.
7. Asaka, M., Kato, M., Sugiyama, T. et al. (2003). Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients, J. Gastroenterol. 38, 339-47.
8. Docherty, R. J., Yeats, J. C. and Piper, A. S. (1997). Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurons in culture, Br. J. Pharmacol. 121, 1461-7.
9. Duck, W. M., Sobel, J., Pruckler, J. M. et al. (2004). Antimicrobial resistance incidence and risk factors among Helicobacter pyloriinfected persons, United States, Emerg. Infect. Dis. 10(6), 1088-94.
10. Hentschel, E., Schutze, K., Weiss, W. et al. (1983). Effect of cimetidine treatment in the prevention of gastric ulcer relapse: a one year double blind multicenter study, Gut 24(9), 853-56.
11. Higuchi, K., Arakawa, T., Nebiki, H. et al. (1998). Rebamipide, a unique gastroprotective drug, prevents recurrence of gastric ulcers without affecting Helicobacter pylori status, Dig. Dis. Sci. 43(Suppl. 9), S995-1005.
12. Higuchi, K., Fujiwara, Y., Tominaga, K. et al. (2003). Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A ramdomized, controled, prospective study, Aliment. Pharmacol. Ther. 17, 111-7.
13. Holzer, P. (1998). Neural emergency system in the stomach, Gastroenterology 114, 823-39.
14. Houben, M. H., van de Beek, D., Hensen, E. F. et al. (1999). A systematic review of helicobacter eradication therapy-the impact of antimicrobial resistance on eradication rates, Aliment. Pharmacol. Ther. 13, 1047-55.
15. Ichikawa, T., Ishihara, K., Komuro, Y. et al. (1994). Effect of FRG-8813, a new-type histamine H2-receptor antagonist, ERG-8813, on gastric mucin in rats with or without acidified ethanol-induced gastric damage, Life Sci. 54(10), 159-64.
16. Kato, S., Tanaka, A., Kunikata, T. et al. (2000). Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons, Digestion 61(1), 39-46.
17. Laine, L., Hopkins, R. J. and Girardi L. S. (1998). Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials, Am. J. Gastroenterol. 93, 1409-15.
18. Miwa, H., Sakaki, N., Sugano, K. et al. (2004). Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients, Helicobacter 9, 9-16.
19. Nagahama, K., Yamato, M., Kato, S. et al. (2003). Protective effect of lafutidine, a novel H2-receptor antagonist, on reflux esophagitis in rats through capsaicin-sensitive afferent neurons, J. Pharmacol. Sci. 93(1), 55-61.
20. Nakagiri, A., Yamato, M., Mashita, Y. et al. (2005). Prophylactic effect of lafutidine against adverse reactions induced in rat stomach by repeated administration of 5-fluorouracil, the anti-cancer drug, Gastroenterology 128, A347.
21. Nebiki, H., Arakawa, T., Higuchi, K. et al. (1997). Quality of ulcer healing influences the relapse of gastric ulcers in humans, J. Gastroenterol. Hepatol. 12, 109-14.
22. Nishihara, K., Nakano, M., Nozawa, Y. et al. (2002). Sensitizing effects of lafutidine on CGRP-containing afferent nerves in the rat stomach, Br. J. Pharmacol. 135(6), 1487-94.
23. Nozawa, Y., Nishihara, K., Akizawa, Y. et al. (2004). Lafutidine inhibits Helicobacter pyloti-induced interleukin-8 production in human gastric epithelial cells, J. Gastroenterol. Hepatol. 19(5), 506-11.
24. Nozawa, Y., Nishihara, K., Yamamoto, A. et al. (2001). Distribution and characterization of vanilloid receptors in the rat stomach, Neurosci. Lett. 309, 33-6.
25. Okayama, M., Tsubouchi, R., Kato, S. et al. (2004). Protective effect of lafutidine, a novel histamine H2-receptor antagonist, on dextran sulfate sodium-induced colonic inflammation through capsaicin-sensitive afferent neurons in rats, Dig. Dis. Sci. 49(10), 1696-04.
26. Onodera, S., Shibata, M., Tanaka, M. et al. (1995). Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats, Jpn. J. Pharmacology 68, 161-73.
27. Onodera, S., Shibata, M., Tanaka, M. et al. (1999). Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity, Arzneim. Forsch Drug Res. 49(1), 519-26.
28. Perez, Aldana, L., Kato, M., Nakagawa, S. et al. (2002). The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance, Helicobacter 7, 306-9.
29. Shibata, M., Yamaura, T., Inaba, N. et al. (1993). Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs, Eur. J. Pharmacol. 235, 245-53.
30. Sugiyama, A., Murakami, M., Maruta, F. et al. (2004). Lafutidine increases mucin-volume in surface mucus gel layer of the human gastric mucosa, Ulcer Research 31(2), 148-50.
31. Takeuchi, K., Ueshima, K., Matsumoto, J. et al. (1992). Role of capsaicin-sensitive sensory nerves in acid-induced bicarbonate secterion in rat stomach, Dig. Dis. Sci. 37, 737-43.
32. Tani, N., Miyazawa, M., Miwa, T. et al. (1999). Immunohistochemical localization of calcitonin gene-related peptide in the human gastric mucosa, Digestion 60, 338-43.
33. Tarnawski, A. (1981). Cimetidine and ranitidine increase ethanol-induced gastric mucosal damage in rat and partially abolish prostaglandin "cytoprotection", Gastroenterology 80, 1300